PIN13 Cost Minimization and Budget Impact Analysis of Pneumococcal Conjugated Vaccines in 3 Latin American Countries (2020-2024)

Value in Health ◽

10.1016/j.jval.2020.08.854 ◽

2020 ◽

Vol 23 ◽

pp. S545-S546

Author(s):

J.A. Gómez ◽

L.E. Moreno ◽

D.O. Constenla ◽

V. Loggia ◽

V. Petrozzi

Keyword(s):

Latin American ◽

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Budget Impact Analysis ◽

Latin American Countries

Download Full-text

Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization

Value in Health Regional Issues ◽

10.1016/j.vhri.2021.06.001 ◽

2021 ◽

Vol 26 ◽

pp. 150-159

Author(s):

Martín Romero ◽

David-Steven Góngora ◽

Martha-Lucia Caicedo ◽

Damia Benchabane ◽

Juan-Guillermo Lopez

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Budget Impact Analysis ◽

Hexavalent Vaccine ◽

Expanded Program On Immunization

Download Full-text

PB2294 COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF MABTHERA SUBCUTANEOUS FORMULATION IN NON-HODGKIN'S LYMPHOMA (NHL): A CASE STUDY FROM TUNISIA

10.1097/01.hs9.0000567644.31502.1f ◽

2019 ◽

Vol 3 (S1) ◽

pp. 1024

Author(s):

R. Ben Lakhal ◽

K. Kacem ◽

M. Raoudha ◽

D. Jabeur ◽

M. S. Denguir ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Budget Impact Analysis ◽

Hodgkin's Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

PCN106 Cost-Minimization and Budget Impact Analysis of Venetoclax plus Obinutuzumab Versus Ibrutinib in Patients with Untreated Chronic Lymphocytic Leukemia in the Brazilian Private Healthcare System

Value in Health ◽

10.1016/j.jval.2021.04.198 ◽

2021 ◽

Vol 24 ◽

pp. S39

Author(s):

F.M. Vieira ◽

G.N. Ribeiro ◽

Filho C Brito ◽

A. Travassos

Keyword(s):

Chronic Lymphocytic Leukemia ◽

Healthcare System ◽

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Budget Impact Analysis ◽

Lymphocytic Leukemia ◽

Private Healthcare

Download Full-text

Cost-Minimization and Budget-Impact Analysis of Fixed-Dose Combination Inhalers in Treatment of Copd in Slovenia

Value in Health ◽

10.1016/j.jval.2014.08.2032 ◽

2014 ◽

Vol 17 (7) ◽

pp. A592

Author(s):

R. Hren ◽

G. Stynes

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Budget Impact Analysis ◽

Fixed Dose Combination ◽

Dose Combination

Download Full-text

Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn’s disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer

Jornal Brasileiro de Economia da Saúde ◽

10.21115/jbes.v9.n1.p44-53 ◽

2017 ◽

Vol 9 (1) ◽

pp. 44-53

Author(s):

Ricardo Rosim ◽

Andreas Duva ◽

André Ferraz ◽

Arcangela Valle ◽

Emese Tóth ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Conventional Treatment ◽

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Certolizumab Pegol ◽

Budget Impact Analysis ◽

Download Full-text

COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA

PHARMACOECONOMICS Modern pharmacoeconomics and pharmacoepidemiology ◽

10.17749/2070-4909.2017.10.2.012-021 ◽

2017 ◽

Vol 10 (2) ◽

pp. 12-21 ◽

Author(s):

N. L. Pogudina ◽

E. G. Kosolapov ◽

F. S. Kochenkov ◽

A. V. Karaulov ◽

N. L. Bondarenko ◽

...

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Budget Impact Analysis ◽

Inhaled Corticosteroid ◽

Comparative Cost ◽

Download Full-text

Cost-Minimization and Budget-Impact Analysis of Fixed-Dose ICS/LABA Combination Inhalers in the Treatment of Asthma in Slovenia

Value in Health ◽

10.1016/j.jval.2014.08.2031 ◽

2014 ◽

Vol 17 (7) ◽

pp. A592

Author(s):

R. Hren ◽

M. Trkman ◽

G. Stynes

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Budget Impact Analysis ◽

Download Full-text

PMS19 COST MINIMIZATION AND BUDGET IMPACT ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT IN RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL

Value in Health ◽

10.1016/s1098-3015(10)70821-4 ◽

2008 ◽

Vol 11 (3) ◽

pp. A260

Author(s):

MG Saggia ◽

EA Santos ◽

V Nasciben

Keyword(s):

Rheumatoid Arthritis ◽

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Budget Impact Analysis ◽

Payer Perspective

Download Full-text

Cost-utility Analysis, Cost-effectiveness Analysis, Budget Impact Analysis

Case Medical Research ◽

10.31525/ct1-nct04283565 ◽

2020 ◽

Author(s):

Keyword(s):

Cost Effectiveness ◽

Impact Analysis ◽

Budget Impact ◽

Cost Utility ◽

Cost Effectiveness Analysis ◽

Cost Utility Analysis ◽

Budget Impact Analysis ◽

Utility Analysis ◽

Effectiveness Analysis

Download Full-text

PCN118 Budget IMPACT Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor ACUTE Lymphoblastic Leukemia in the Netherlands

Value in Health ◽

10.1016/j.jval.2020.08.255 ◽

2020 ◽

Vol 23 ◽

pp. S444

Author(s):

I. van Oostrum ◽

K. De Lameillieure ◽

T.A. Russell-Smith

Keyword(s):

Acute Lymphoblastic Leukemia ◽

The Netherlands ◽

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Budget Impact Analysis ◽

Cell Precursor ◽

Inotuzumab Ozogamicin

Download Full-text